

## 5TH OF MAY

10.00 - 12.00 **Entry Into Manufacture of Car T-Cell Course**

Chairs: **Gamze Tanrıöver Şule Menziletoğlu Yıldız**

Instructor: **John Lister**

12.00 – 13.00 LUNCH BREAK

13.00 - 13.30 **POSTER COMMUNICATIONS SESSION 1**

Chairs:

P-01 A Successful Treatment Of Relapsed Refractory Mds Patient Who is Followed Under Hemodialysis - **Bahar Sevgili**

P-02 The TIP of The Iceberg: Vaginal Bleeding and Granulocytic Sarcoma of the Uterus  
**Serhat Çelik**

P-27 Understanding physician's approach to diagnosis and treatment of Acute Myeloid Leukemia Disease in Türkiye : Turkish Hematology Networking Group Survey  
**Birol Güvenç**

P-03 Chronic Hepatitis B Infection Management in A Long Term Followed Of Chronic Lymphocytic Leukemia Treated With Multiple Lines Of Chemoimmunotherapies Including Ibrutinib – **Bahar Sevgili**

P-04 Case Report With Chronic Lymphocytic Leukemia And Primary Immune Failure Combined – **Seda Yılmaz**

P-28 A Survey of Chronic Lymphocytic Leukemia Treatment Approaches in Turkey: A Turkish Hematology Network Group Study – **Birol Güvenç**

P-05 Hemophilia And Gastrointestinal Bleeding, Beyond Hemarthrosis - **Bahar Sevgili**

P-06 Covid Vaccination Associated Acquired Thrombotic Thrombocytopenic Purpura  
**Ruveyda Silay**

P-08 A Rare Bleeding Diathesis with Subacute Splenic Hematoma: PAI-1 Deficiency  
**Berrin Balık Aydın**

P-09 Evaluation of Safety Profile of Rituximab+Lenalidomide Protocol in Frail Elder Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients - **Bahar Sevgili**

- P-10 Ibrutinib Therapy in Relapsed/Refractory Primary Central Nervous System Lymphomas – **Serkan Güven**
- P-11 Diffus Large Cell Lymphoma of the Uterus Presented with Vaginal Bleeding: A Case Report – **Zeynep Tuğba Güven**

13.30 - 14.30 **ORAL COMMUNICATIONS SESSION 1**

Chairs: **Mehmet Hilmi Doğu - Mehmet Gündüz**

13.30 – 13.40 A Comparison of Serum Immunoglobulin Levels Among Pediatric Acute Leukemias – **Ayşe Ceyda Ören**

13.40 – 13.50 The Use of Gemtuzumab Ozogamicin As Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience  
**İbrahim Halil Açar**

13.50 – 14.00 Acute Promyelocytic Leukemia and Stem Cell Transplantation: Case Series, Single Center Experience – **Ali Ünal**

14.00 – 14.10 Efficacy and Safety of Single Agent Blinatumomab as Salvage Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukaemia: Real Life Experience - **İbrahim Halil Açar**

14.10 – 14.20 Investigating FLT3 Mutations in Acute Myeloid Leukemia: A Single-Center Real-World Data Study on Patient Outcomes and Treatment Strategies -  
**İbrahim Halil Açar**

14.20 – 14.30 R-Venetoclax Treatment in A B-Cell Prolymphocytic Leukemia Patient: A Challenging Case – **Eren Arslan Davulcu**

14.30 – 14.40 Difference in Anxiety Between Oral Or iv Treatment in CLL Patients  
**Yıldız İpek**

14.40 – 14.50 Retrospective Evaluation of Bcr::Abl1 Negative Myeloproliferative Neoplasms (Mpns) Treated With Pegylated Interferon Alpha-2a At A Single Center – **Mehmet Baysal**

14.50 - 15.00 COFFEE BREAK

15.00 - 15.30 **POSTER COMMUNICATIONS SESSION 2**

Chair:

- P-12 Clonal CD4+ Cytotoxic T Lymphocytosis Concomitant with Poems Syndrome: A Co-Existence or Key Finding for Relevance in the Pathogenesis – **Burak Gültekin**
- P-13 A Rare Case Of Multiple Myeloma Presenting as a Cranial Nerve Palsy – **Elif Sakcı**
- P-29 Addressing Multiple Myeloma in Turkey: A Nationwide Survey by the Turkish Hematology Network Group Highlights Opportunities and Challenges - **Biol Güvenç**
- P-30 Efficacy of Bendamustine-Pomalidomide-Dexamethasone Treatment in Patients with Relapsed/Refractory Extramedullary Myeloma: A Retrospective Study – **İbrahim Halil Açar**
- P-14 The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data **Müzeyyen Aslaner Ak**
- P-15 Insight into Hypereosinophilia From The Hematology Clinic; A Single-Center Experience – **Beyza Oluk**
- P-16 A Different Point Of View: Facial Paralysis As A Manifestation of AL Amyloidosis **Kıvanç Koruk**
- P-25 Efficacy of Cladribine Combined with Rituximab versus Cladribine Alone in the Treatment of Hairy Cell Leukemia: A Retrospective Single-Center Study – **İbrahim Halil Açar**
- P-26 Evaluating the Efficacy of Therapeutic Plasma Exchange in the Management of HELLP Syndrome: A Single-Center Experience – **İbrahim Halil Açar**
- P-18 A Case of May Hegglin Anomaly with Pregnancy – **Metban Mastanzade**
- P-19 Evaluation of Bk Polyomavirus Infection Frequency And Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience – **Barış Gezici**
- P-20 Evaluation of The Effects of Cytomegalovirus and Bk Polyomavirus Infections on Overall Survival Following Allogeneic Stem Cell Transplantation: A Single Center Experience - **Barış Gezici**
- P-21 A Rare Etiology of Hepaiomegaly: Extramedullary Hematopoiesis After Allogeneic Stem Cell Transplantation – **Bahar Sevgili**

P-22 Scabies Induced Hypereosinophilic Syndrome After Allogeneic Stem Cell Transplant: Case Report – **Yunus Çatma**

15.30 - 16.40 **ORAL COMMUNICATIONS SESSION 2**

Chairs: **Alpay Yeşilaltay - Erman Öztürk**

15.30 – 15.40 Face and Neck Cutaneous T-Cell Lymphomatoid Papulosis  
**Mehmet Yılmaz**

15.40 – 15.50 Coexistence of T-Lymphoblastic Lymphoma/Leukemia and Thymoma  
**Mehmet Yılmaz**

15.50 – 16.00 Microbiota Changes in Hodgkin and Non-Hodgkin Lymphoma Treatment: Assessment with Il17 and Il12 Levels – **Ekin Ece Gürer**

16.00 – 16.10 Determination of T Lymphocyte Subgroups in the Bone Marrow Micro Environment in Multiple Myeloma: Can Tumor-Directed T Cells Play a Role in Fighting Cancer? – **Ali Ünal**

16.10 – 16.20 CXCL12 Chemokine and Relationship with Multiple Myeloma  
**Ekin Ece Gürer**

16.20 – 16.30 Adipose Tissue Metabolic Activity in Multiple Myeloma  
**Işıl Erdoğan Özunal**

16.30 – 16.40 The Invisible Damage of The Covid 19 Pandemic to Our Apheresis Unit and The National Economy – **Gülşah Akyol**

16.40 - 17.10 COFFEE BREAK

17.10 - 18:20 **ORAL COMMUNICATIONS SESSION 3**

Chairs: **Şebnem İzmir Güner - Ali İhsan Gemici**

17.10 – 17.20 Evaluation of Cytomegalovirus Infection/Disease Frequency And Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience – **Barış Gezici**

17.20 – 17.30 Impact of Epitope Match On Stem Cell Transplantation – **Yeliz Öğret**

17.30 – 17.40 A Rare, Challenging Disease ; Langerhans Cell Histiocytosis - A Single Center Experience – **Betül Kübra Tüzün**

- 17.40 – 17.50 Hematuria in Adult Haemophilic Individuals: Is it The Only Cause of Hemophilia? A Single Center Experience - **Betül KübraTüzün**
- 17.50 – 18.00 Is Ferriç Carboxymaltose A Safer Option Compared to Iron Sucrose? **Ahmet Sarıcı**
- 18.00 – 18.10 The Role of 18F- FDG Pet/Ct Scan in Adult Langerhans Cell Histiocytosis: A Single-Center Experience – **Simge Erdem**
- 18.10 – 18.20 Evaluation of Treatment Responses of Children Diagnosed with Hemangioma, Single Center Experience – **Dilvin Çelik Ateş**
- 18.20 – 18.30 Characteristics and Outcomes of Myelodysplastic Syndrome Patients Treated with Darbepoetin Alfa for Anemia in Turkey: A Multicenter Retrospective Study - **İbrahim Halil Açar**

## 6TH OF MAY

09.00 - 09:15 **Opening Remarks: Elias Jabbour**

### **CML Session**

Chairs: **Şehmus Ertop - Ant Uzay**

09:15 - 09:30 Frontline CML Management  
-**Hagop Kantarjian (Virtual)**

09:30 - 09:45 Management of Relapsed/Refractory CML and Advanced Phases  
-**Elias Jabbour**

09:45 - 10:00 Treatment Free Remission: Where and When ?  
-**Giuseppe Saglio**

10:00 - 10:10 **Questions Session**

10:10 - 10:25 COFFEE BREAK

**ALL Session**

Chairs: **Işık Kaygusuz - İtir Şirinoğlu Demiriz**

10:25 - 10:40 T ALL

-**Ali Bazarbachi**

10:40 - 10:55 Frontline Therapies

-**Hagop Kantarjian (Virtual)**

10:55 -11:10 MRD Assessment and Management

-**Farhad Ravandi (Virtual)**

11:10 - 11:20 **Questions Session**

11:20- 11:50 **ASTELLAS SATELLITE SYMPOSIUM**

Current Treatment Approaches to FLT3 Mutated AML

Chair: **Mehmet Yılmaz** Speaker: **Naval Daver**

11:50 - 12:05 COFFEE BREAK

**Management of Relapsed/Refractory ALL Monoclonal vs CAR -T**

Chairs: **Serdar Bedii Omay - İpek Yönel Hindilerden**

12:05 - 12:20 Monoclonal and Bispecific Antibodies, and Novel Agents

-**Elias Jabbour**

12:20 - 12:35 Car T-Cells Therapies

-**Arnon Nagler**

**Philadelphia-Positive ALL: Transplant vs No Transplant**

12:35 - 12:50 Curable Without Allogeneic Stem Cell Transplantation

-**Elias Jabbour**

12:50 -13:05 Allogeneic Stem Cell Transplantation Still Needed in the Majority

-**Ali Bazarbachi**

13:05 - 13:20 **Questions Session**

13:20 - 14:20 LUNCH BREAK



### **MDS Session**

Chairs: **Mehmet Yılmaz - Oral Nevruz**

14:20 - 14:35 Updates to Classification, Response Criteria and Prognosis  
**-Guillermo Garcia-Manero(Virtual)**

14:35 - 14:50 Stem Cell Transplantation in MDS  
**-Mustafa Cetiner**

14:50 - 15:05 Management of Lower-Risk MDS  
**-Tapan Kadia**

15:05 - 15:20 How Do I Approach HR-MDS Including TP53 Disease  
**-Guillermo Garcia-Manero(Virtual)**

15:20 - 15:30 **Questions Session**

15:30 - 15:45 BREAK

### **15:45 - 16:15 AMGEN SATELLITE SYMPOSIUM**

Carfilzomib Treatment in Relapsed/Refractory Multiple Myeloma

Chair: **Mehmet Turgut** Speaker: **Hakan Göker**

16:15 - 16:30 COFFEE BREAK

### **AML Session**

Chairs: **Leyla Gül Kaynar - Fehmi Hindilerden**

16:30 - 16:45 How I Treat AML  
**-Farhad Ravandi (Virtual)**

### **Frontline Fit Patient's Treatment**

16:45 - 16:55 Intensive chemotherapy beyond 7+3 for Young Patients with AML  
**-Tapan Kadia**

16:55 - 17:05 Targeted Therapies  
**-Naval Daver**

17:05 - 17:15 Elderly AML Patient Management  
**-Farhad Ravandi (Virtual)**

17:15 - 17:25 Minimal Residual Disease and Role of Maintenance  
**-Tapan Kadia**

17:25 - 17:35 Immune and Cellular Approaches for Myeloid Leukemia: Current and Future Directions  
**-Naval Daver**

17:35 - 17:50 **Questions Session**

17:50 - 18:05 COFFEE BREAK

**MPN Session**

Chairs: **A.Emre Eşkazan - Ferit Avcu**

18:05 - 18:20 JAK2 Inhibitors in PV and ET  
**-Daniela Cilloni**

18:20 - 18:35 Updates on WHO Classification of MPN's  
**-Hanan Hamed**

18:35 - 18:50 How I Treat Primary and Secondary Myelofibrosis  
**-Daniela Cilloni**

18:50 - 19:00 **Questions Session**

**7TH OF MAY**

08:00 - 09:00 Meet the Expert Sessions

ALL	<b>Elias Jabbour</b>
AML	<b>Tapan Kadia</b>
CML	<b>Giuseppe Saglio</b>
CLL	<b>William Wierda</b>
MPN	<b>Naval Daver</b>
MM	<b>Claudio Cerchione</b>



**Special Session**

Chair: **Emin Kaya - Sinem Civriz Bozdağ**

09:00 - 09:20 Cancer in Elderly People

-**Zeba Aziz**

09:20 - 09:30 PNH Diagnosis and Treatment

-**Hanan Hamed**

**CLL Session**

Chairs: **Mehmet Ali Özcan - Pervin Topçuoğlu**

09:30 - 09:45 Frontline Therapies

-**William Wierda**

09:45 - 10:00 Management of Relapsed/Refractory Disease: Novel Agents

-**William Wierda**

10:00 - 10:10 **Questions Session**

10:10 - 10:25 COFFEE BREAK

10:25 - 11:00 **NOVARTIS SATELLITE SYMPOSIUM**

Ruxolitinib Experience in Myelofibrosis Treatment

Chair: **Ayşe Tulin Tuğlular** Speaker: **A. Emre Eşkazan**

11:00 - 11:10 COFFEE BREAK

11:10 - 11:40 **ABBVIE SATELLITE SYMPOSIUM**

Deep Response Powered by V: Treatment Applications with VENCLYXTO

Chair: **Osman İlhan** Speaker: **Mustafa Çetiner**

- Long-Term Survival Results and Treatment Management of VENCLYXTO in AML
- Treatment Initiation and Long-Term Results with VENCLYXTO in CLL

### **Lymphoma Session**

Chairs: **Gülsan Sucak - Hüseyin Saffet Beköz**

11:40 - 11:55 How I Treat Follicular Lymphoma  
**-John Lister**

11:55 - 12:10 How I Treat Diffuse Large Cell Lymphoma  
**-İbrahim Barışta**

12:10 - 12:25 How I Treat Mantle Cell and Marginal Zone Lymphoma  
**-Olivier Hermine**

12:25 - 12:40 How I Treat Hodgkin Disease  
**-Tayfur Toptaş**

12:40 - 12:50 **Questions Session**

12:50 - 14:05 LUNCH BREAK

14:05 - 14:35 **JANSSEN SATELLITE SYMPOSIUM**

**Living Ahead of the Curve with IMBRUVICA**

Chair: **Mehmet Ali Özcan** Speaker: **Tayfur Toptaş**

14:35 - 14:50 COFFEE BREAK

### **MM Session**

Chairs: **Sevgi Kalayoğlu Beşışık - Anıl Tombak**

14:50 - 15:10 How I Treat Newly Diagnosed MM?  
**-Claudio Cerchione**

15:10 - 15:30 How I Treat relapsed/refractory MM in the era of novel agents, Bispecific  
Antibodies and CAR T-Cells  
**-Ahmad Ibrahim**

15:30 - 15:50 How I Manage Smoldering Myeloma: To Treat or Not To Treat?  
**-Claudio Cerchione**

15:50 - 16:00 **Questions Session**

16:00 **Closing Remarks**